Long-Term Quality of Prescription for ST-Segment Elevation Myocardial Infarction (STEMI) Patients: A Real World 1-Year Follow-Up Study
Published inAmerican journal of cardiovascular drugs, vol. 20, no. 1, p. 105-115
Publication date2020-02
Abstract
Keywords
- Adrenergic beta-Antagonists / therapeutic use
- Aged
- Angiotensin Receptor Antagonists / therapeutic use
- Angiotensin-Converting Enzyme Inhibitors / therapeutic use
- Aspirin / therapeutic use
- Cardiovascular Agents / therapeutic use
- Drug Prescriptions
- Female
- Follow-Up Studies
- Guideline Adherence
- Humans
- Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
- Middle Aged
- Myocardial Infarction / drug therapy
- Prescription Drugs / therapeutic use
- Prospective Studies
- Registries
- ST Elevation Myocardial Infarction / drug therapy
- Secondary Prevention / methods
- Switzerland
Research group
Citation (ISO format)
BRUGGMANN, Christel et al. Long-Term Quality of Prescription for ST-Segment Elevation Myocardial Infarction (STEMI) Patients: A Real World 1-Year Follow-Up Study. In: American journal of cardiovascular drugs, 2020, vol. 20, n° 1, p. 105–115. doi: 10.1007/s40256-019-00361-5
Main files (1)
Article (Published version)
Secondary files (1)
Identifiers
- PID : unige:163553
- DOI : 10.1007/s40256-019-00361-5
- PMID : 31300969
- PMCID : PMC6978447
ISSN of the journal1175-3277